Year: 2007
Type: article
Abstract: Diabetic retinopathy (DR) and diabetic macular edema (DME) are leading causes of blindness in the working-aged population of most developed countries. The increasing number of persons with diabetes worldwide suggests that DR/DME will continue to be major contributors to vision loss and associated functional impairment for years to come. Early detection of retinopathy in persons with diabetes is critical in preventing visual loss, but current methods of screening fail to identify a sizable number of high-risk patients. The control of diabetes-associated metabolic abnormalities (ie, hyperglycemia, hyperlipidemia, and hypertension) is also important in preserving visual function, as these conditions have been identified as risk factors for both the development and progression of DR/DME. The non-pharmacologic interventions for DR/DME, laser photocoagulation and vitrectomy, only target advanced stages of disease. Several biochemical mechanisms, including increased vascular endothelial growth factor production, protein kinase C beta activation, oxidative stress, and accumulation of intracellular sorbitol and advanced glycosylation end products, may contribute to the vascular disruptions that characterize DR/DME. The inhibition of these pathways holds the promise of the intervention for diabetic retinopathy with higher success rate and also at earlier, non-sight-threatening stages.
Source: PubMed Central
Institution: Sheba Medical Center
Language: English
Subfield: Ophthalmology
Field: Medicine
Domain: Health Sciences
Keywords: diabetic retinopathy, diabetic macular edema, pharmacotherapy, retinopathy screening, hyperglycemia, hyperlipidemia, hypertension, laser photocoagulation, vitrectomy, vascular endothelial growth factor, protein kinase C beta, oxidative stress, sorbitol accumulation, advanced glycation end products, blindness prevention
Open Access status: green
Funder: Research to Prevent Blindness
OpenAlex ID: W207920454
